Credit: Chun-Wei (David) Chen, Ph.D./ City of HopeAdvancement in Cancer TreatmentBlending laboratory experiments with computer system simulations, Chens group developed a powerful digital application of CRISPR gene-tiling innovation to uncover potential cancer medications that exactly target the β-propeller domain.After recognizing the chemical compound Cpd_AV2 as a strong candidate, the team applied this substance to human cancer cells in the laboratory. Integrin αV and β5 quickly separated, liquifying communication between the 2 proteins and causing cellular death, efficiently halting development in cancer cell lines.Clinically, the scientists found integrin αV overexpression in several cancer types, highlighting integrin αVs lead role in cancer progression. High levels of integrin αV were also associated with a poor diagnosis in 3,700 patients with cancers of the breast, pancreas, liver, lung, and brain.Expanding Therapeutic HorizonsBy broadening chances for developing targeted therapies that sever the connection between integrin αV and β5, the City of Hope-led findings recommend a potent new approach for cancer treatment and future medication discovery research studies.